Clinical research industry’s largest, most diverse global network of patient advocates improves the trial experience across therapeutic areas and technologies
Medable Inc., the leading technology platform for clinical trials, today announced it was named Trailblazer in Everest Group’s inaugural “Clinical Trial Patient Engagement Products Assessment.” Medable was selected out of 44 organizations and one of the only companies to receive a perfect score in all categories for its holistic focus on patient engagement in clinical trials, as reflected in its Patient Caregiver Network (PCN) – the industry’s first, largest, and most diverse patient advocacy ecosystem and cornerstone to Medable R&D.
“This recognition is a testament to Medable’s commitment to reimagining the clinical trial experience through patient-informed solutions,” said Jena Daniels, Medable Vice President of Customer Value – Site and Patient Engagement. “Every version of our clinical trials platform has been guided by lived patient experiences and real-world feedback from clinical trial sites through our Site Network. We are honored by PCN members’ courage and willingness to share their stories to inform Medable technology, and so our solutions resonate with many diverse patient populations – a benefit that has often been a key decision factor for our customers.”
Medable’s PCN, launched in 2018, has rapidly grown to include nearly 100 patient advocates and caregivers from 12 countries, representing 67 diverse health conditions. Through a strategic partnership with Rare Patient Voice, Medable PCN also includes a broader network of over 1,600 additional patients across eight countries who have participated in a decentralized or hybrid trial – enabling Medable to incorporate diverse patient experiences into its solutions.
“We proudly partner with Medable, who are true trailblazers in patient engagement,” said Wes Michael, President of Rare Patient Voice. “Our community of over 145,000 patients and family caregivers across hundreds of rare and non-rare diseases in nine countries is eager to share its collective voice and stands ready to participate in clinical research. Our collaboration provides access to patients who have participated in decentralized trials globally. We’d like to congratulate Medable on its commitment to excellence and look forward to continuing to work together for maximum results.”
According to Everest Group, Medable has excelled at incorporating the voice of the patient into the clinical trial and developed unique ways to improve patient participation and adherence.
“As one of the original members of Medable’s PCN, I have found the experience to be immensely rewarding – a genuine gift of personal experience for the benefit of others,” added Karen Utley, mother and full-time caregiver of Samantha who was born with the rare neurodevelopmental condition called CDKL5 Deficiency Disorder. Samantha successfully participated in a clinical trial that would have been disrupted by COVID-19 except for decentralized technologies. “Medable has genuinely and carefully considered both my daughter’s and my experiences with a decentralized trial, incorporating their learnings to enhance processes and products to improve the trial experience for all. For that, I am proud.”
Daniels concluded, “Our commitment to improve the trial experience doesn’t stop with patients. Medable is equally dedicated to incorporating real-world site feedback to alleviate operational burden and enable greater focus on patients.”
Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A Tufts CSDD study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M in Phase III trials, respectively.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
